Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine.
Ketorolac tromethamine 0.5% ophthalmic solution treatment was compared to placebo treatment in 120 patients with chronic aphakic or pseudophakic cystoid macular edema (six-month or more duration of distance visual acuity of 20/40 or less and angiographic evidence of cystoid changes) during a four- to five-month double-masked, multicenter study in which patients were randomly assigned. A statistically significant improvement in distance visual acuity (two lines or more) was observed in the ketorolac-treated group as compared to the placebo-treated group after 30 days (P = .038), 60 days (P = .017), and 90 days (P = .008) of treatment. This improvement in visual acuity remained statistically significant one month after cessation of treatment (P = .001). Nine ketorolac-treated patients and two placebo-treated patients demonstrated a decrease in visual acuity one month after treatment was discontinued. Seven of the nine ketorolac-treated patients experienced an improvement in visual acuity after retreatment as compared to none of the placebo-treated patients. This study offers evidence for a more optimistic outlook in the medical treatment of chronic aphakic and pseudophakic cystoid macular edema.
Flach
A J
AJ
Department of Ophthalmology, University of California, San Francisco.
Jampol
L M
LM
Weinberg
D
D
Kraff
M C
MC
Yannuzzi
L A
LA
Campo
R V
RV
Neumann
A C
AC
Cupples
H P
HP
Lefler
W H
WH
Pulido
J S
JS
D000287:Administration, Topical; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001035:Aphakia / Q000188:drug therapy* / Q000503:physiopathology; D002908:Chronic Disease; D004311:Double-Blind Method; D004338:Drug Combinations; D005128:Eye Diseases / Q000139:chemically induced; D006801:Humans; D020911:Ketorolac Tromethamine; D008269:Macular Edema / Q000188:drug therapy* / Q000503:physiopathology; D014046:Tolmetin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014325:Tromethamine / Q000009:adverse effects / Q000627:therapeutic use*; D014792:Visual Acuity
D000894:Anti-Inflammatory Agents, Non-Steroidal; D004338:Drug Combinations; D014325:Tromethamine; D020911:Ketorolac Tromethamine; D014046:Tolmetin